WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present data across its COVID-19 and respiratory syncytial virus (RSV) pipeline at the 10th Annual IDWeek Virtual Conference, September 29 to October 3, 2021, illustrating its commitment to advancing innovative science in infectious diseases.
Data featuring AstraZenecas investigational long-acting antibody (LAAB) programs AZD7442 for COVID-19 and nirsevimab for RSV as well as AZD1222, will be presented as three late-breaking oral presentations.
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: The compelling data being presented at IDWeek reflect our scientific advances across infectious diseases in response to the COVID-19 pandemic and surges in respiratory syncytial virus cases. Our PROVENT Phase III data demonstrate AZD7442 may offer much-needed protection for vulnerable populations who may not mount an adequate immune response to COVID-19 vaccination.
Advancing COVID-19 prevention with cutting-edge science
High-level efficacy and safety data from the PROVENT Phase III trial investigating AZD7442 for prevention of COVID-19 will be presented for the first time following the initial announcement in August. The data showed that AZD7442 compared to placebo achieved a statistically significant reduction in the risk of developing symptomatic COVID-19 prior to virus exposure (pre-exposure prophylaxis).1 More than 75% of participants in the trial had co-morbidities, which includes those with a reduced immune response to vaccination.1 In PROVENT, the LAAB was well tolerated and preliminary analyses show adverse events were balanced between the placebo and AZD7442 groups.
A late-breaker oral presentation of Phase III results will show whether AZD1222 prevents asymptomatic cases of COVID-19, as well as its capability to shorten viral shedding in breakthrough infections. Understanding the duration of viral shedding may help the implementation of effective public health efforts to control the spread of the virus.2
Late breaking data on nirsevimab
The MELODY Phase III trial data for nirsevimab, an investigational long-acting antibody being developed by AstraZeneca and Sanofi, will demonstrate the potential of nirsevimab to help protect all infants entering their first RSV season with a single dose.
Key AstraZeneca presentations during IDWeek 2021
Lead author
Abstract title
Presentation details
COVID-19 (Long-acting antibody)
Levin, M
PROVENT: Phase 3 Study of Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for Pre-exposure Prophylaxis of COVID-19 in Adults
Abstract #LB5
Session: Late Breaker Abstracts: COVID-19 Treatment & Prophylaxis
September 30, 2021
5:15 6:30pm EDT
Presentation time:
6:15 6:30pm EDT
COVID-19 (Vaccine)
Sobieszczyk, M
Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in a Phase 3 Study of AZD1222 (ChAdOx1 nCoV-19)
Abstract #LB6
Session: Late Breaker Abstracts: COVID-19 Vaccines, Epidemiology, and Clinical
October 1, 2021
10:00 11:15am EDT
Presentation time:
10:00 10:15am EDT
Respiratory Syncytial Virus (Long-acting antibody)
Hammitt, L
The Efficacy and Impact in Healthy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
Abstract #LB13
Session: Late Breaker Abstracts
October 2, 2021
1:15 3:00pm EDT
Presentation time: 1:45pm EDT
AZD7442
AZD7442 is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.3-4 Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein4-5 and were optimized by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. The half-life extension more than triples the durability of its action compared to conventional antibodies and could afford up to 12 months of protection from COVID-19 following a single administration.6-9 The reduced Fc receptor binding aims to minimize the risk of antibody-dependent enhancement of disease - a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.10
AZD7442 is being studied in a comprehensive clinical trial program for both prevention and treatment of COVID-19. In August 2021, AstraZeneca announced positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial. Other ongoing trials include TACKLE COVID-1911, a Phase III mild-to-moderate COVID-19 outpatient treatment trial, and collaborator treatment trials in outpatient and hospitalized settings.
Preliminary in vitro findings demonstrate that AZD7442 neutralizes recent emergent SARS-CoV-2 viral variants, including the Delta and Mu variants.12,13
AstraZeneca is preparing regulatory submission of the prophylaxis data to health authorities for potential emergency use authorization or conditional approval of AZD7442.
AZD1222
AZD1222 was co-invented by the University of Oxford and its spin-out company, Vaccitech. It uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus (adenovirus) that causes infections in chimpanzees and contains the genetic material of the SARS-CoV-2 virus spike protein. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
AZD1222 has been granted a conditional marketing authorization or emergency use in more than 80 countries across six continents. More than 1.1 billion doses of AZD1222 have been supplied to more than 170 countries worldwide, including more than 100 countries through the COVAX Facility.
Nirsevimab
Nirsevimab is an investigational long-acting antibody, being developed by AstraZeneca and Sanofi using AstraZenecas proprietary YTE technology, designed to protect all infants for the RSV season. Due to its extended half-life technology, nirsevimab is being developed as a single dose for all infants experiencing their first RSV season and infants with congenital heart disease or chronic lung disease entering their first and second RSV season.14 The current anti-RSV antibody, AstraZenecas Synagis, is limited to high-risk infants and provides one-month protection, requiring five injections to cover an RSV season.15
Nirsevimab is designed to provide RSV protection to all infants via an antibody given directly to an infant to help prevent LRTI caused by RSV. Unlike an active immunization, monoclonal antibodies do not require the activation of the immune system to help offer rapid and direct protection against disease.16 There has been a recent resurgence of RSV during the easing of COVID-19 public health measures.17
Nirsevimab has been granted regulatory designations to facilitate expedited development by three major regulatory agencies around the world. These include Breakthrough Therapy Designation by The China Center for Drug Evaluation under the National Medical Products Administration; Breakthrough Therapy Designation from the US Food and Drug Administration; and access granted to the European Medicines Agency PRIority MEdicines (PRIME) scheme. Nirsevimab is currently under clinical investigation and has not been approved by any regulatory authority.
In March 2017, AstraZeneca and Sanofi announced an agreement to develop and commercialize nirsevimab. Under the terms of the agreement, AstraZeneca leads all development and manufacturing activities and Sanofi will lead commercialization activities and record revenues. Under the terms of the global agreement, Sanofi made an upfront payment of 120m, has paid a development milestone of 30m and will pay up to a further 465m upon achievement of certain development and sales-related milestones. The two companies share all costs and profits. Revenue from the agreement is reported as Collaboration Revenue in the Companys financial statements.
Related, in November 2018, AstraZeneca divested US commercial rights for Synagis to Swedish Orphan Biovitrum AB (publ) (Sobi) in addition to the right to participate in payments that may be received by AstraZeneca from the US profits or losses for nirsevimab. Under the agreement, AstraZeneca received upfront consideration of $1.5bn, consisting of $1.0bn in cash and $500m in ordinary shares of Sobi upon completion, and will have received a total of $60m in non-contingent payments for nirsevimab during 2019-2021. AstraZeneca will also receive up to $470m in sales-related payments for Synagis, a $175m milestone following the submission of the Biologics License Application (BLA) for nirsevimab and potential net payments of approximately $110m on achievement of other nirsevimab profit and development-related milestones. Upon payment of the $175m milestone on BLA submission, Sobis ongoing participation will amount to AstraZenecas full share of profits or losses under the agreement with Sanofi for nirsevimab in the US. AstraZeneca will continue to manufacture and supply nirsevimab globally and is entitled to an additional royalty from Sobi if profits from nirsevimab in the US exceed a pre-specified level.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit http://www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
References
Read more here:
- Choosing Regular Food to Extend Longevity - CounterPunch.org - CounterPunch - April 18th, 2024 [April 18th, 2024]
- "I love the club, I'm really happy here" - Manchester United star opens up on life at club amid contract extension uncertainty - Sportskeeda - March 31st, 2023 [March 31st, 2023]
- Life Extension review - 7 facts you should know [APRIL 2022] - February 5th, 2023 [February 5th, 2023]
- Biomedical Research & Longevity Society - Wikipedia - January 27th, 2023 [January 27th, 2023]
- NAD+ Cell Regenerator and Resveratrol Elite - Life Extension - December 26th, 2022 [December 26th, 2022]
- FLORASSIST GI with Phage Technology - Life Extension - December 12th, 2022 [December 12th, 2022]
- Magnesium Citrate 100 mg, 100 capsules - Life Extension - November 5th, 2022 [November 5th, 2022]
- AMPK Metabolic Activator, 30 tablets - Life Extension - November 5th, 2022 [November 5th, 2022]
- Germany nuclear plants life extension approved by Cabinet - DW (English) - October 19th, 2022 [October 19th, 2022]
- Biohacking: What is it, types and hacks to try for beginners - Medical News Today - October 19th, 2022 [October 19th, 2022]
- 'Biggest day of my life': Kevin Porter Jr., Rockets react to extension - Rockets Wire - October 19th, 2022 [October 19th, 2022]
- Postharvest quality solution for tomatoes-on-the-vine - hortidaily.com - October 19th, 2022 [October 19th, 2022]
- JZZ Technologies, Inc. and Subsidiary LION Development Group, Enter into JV Agreement with affiliate of Hospitality Development Group, Inc. of Florida... - October 19th, 2022 [October 19th, 2022]
- 'I love the city': QB Zach Collaros inks 3-year contract extension to stay with Blue Bombers through 2025 - CBC.ca - October 19th, 2022 [October 19th, 2022]
- MSU-led team studying expansion of controlled environment culinary herb production across US - Michigan State University - October 19th, 2022 [October 19th, 2022]
- 60 seconds with...Wayne Dunn, Babcock International - Professional Engineering - October 19th, 2022 [October 19th, 2022]
- Wind energy operators must address these 5 areas to exploit the full value of monitoring - Windpower Engineering - October 19th, 2022 [October 19th, 2022]
- Extension shares tips for practicing fire safety in the fall - The Hartselle Enquirer - Hartselle Enquirer - October 19th, 2022 [October 19th, 2022]
- FIRST Robotics Prepares to Extend Its Reach to More Vermont Students - Seven Days - October 19th, 2022 [October 19th, 2022]
- Plant Life Cycles - Penn State Extension - October 2nd, 2022 [October 2nd, 2022]
- FDA Authorizes Shelf Life Extension for Certain Lots of Paxlovid - October 2nd, 2022 [October 2nd, 2022]
- EDF considers extending life of two UK nuclear plants due to energy crisis - The Guardian - October 2nd, 2022 [October 2nd, 2022]
- Rittenbach among Extension team professionals honored - Jamestown Sun | News, weather, sports from Jamestown North Dakota - The Jamestown Sun - October 2nd, 2022 [October 2nd, 2022]
- What is the circular economy and why is it essential for real sustainability? - Schroders - October 2nd, 2022 [October 2nd, 2022]
- 44 national and international NGOs call for renewal and expansion of truce in Yemen [EN/AR] - Yemen - ReliefWeb - October 2nd, 2022 [October 2nd, 2022]
- University City Townhomes residents now have until end of the year to find new low-income housing - The Philadelphia Inquirer - October 2nd, 2022 [October 2nd, 2022]
- New Eskom board: Business groups happy with mix of skills - News24 - October 2nd, 2022 [October 2nd, 2022]
- Full circle on the farm: Penn State alum returns to help educate Pa. growers - Pennsylvania State University - October 2nd, 2022 [October 2nd, 2022]
- Task Force: Blacks are owed hundreds of thousands - CalMatters - October 2nd, 2022 [October 2nd, 2022]
- ProLynx appoints Richard King as Chief Executive Officer and Chris Ehrlich as Board Director - GlobeNewswire - September 20th, 2022 [September 20th, 2022]
- Analysis: Behind Trump's media deal, a vote where only yes will do - Reuters - September 20th, 2022 [September 20th, 2022]
- Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19 | Antibodies | News Channels - PipelineReview.com - September 20th, 2022 [September 20th, 2022]
- Action Hampshire get behind Sustainable Future Fund to reduce waste in business - Hampshire Chronicle - September 20th, 2022 [September 20th, 2022]
- Living the dream - Farm Progress - September 20th, 2022 [September 20th, 2022]
- Teck and Agnico Eagle Announce Agreement on the San Nicols Copper-Zinc Project located in Zacatecas, Mexico - PR Newswire - September 20th, 2022 [September 20th, 2022]
- Most actively traded companies on the Toronto Stock Exchange - Winnipeg Free Press - September 20th, 2022 [September 20th, 2022]
- Giants Urged to Give Extension to 24-Year-Old Defender - Heavy.com - September 20th, 2022 [September 20th, 2022]
- Russias MiG-31 Fighter That Fired Hypersonic Missiles On Ukraine Conducted Drills In The Stratosphere - EurAsian Times - September 20th, 2022 [September 20th, 2022]
- Jaguar Mining Reports Confirmed Continuity of Mineralization at Pilar Gold Mine - Life of Mine Extension Drilling to Follow - Yahoo Finance - September 14th, 2022 [September 14th, 2022]
- Easy meals, life-saving knife skills part of West Texas Fair & Rodeo Spotlight Kitchen - Abilene Reporter-News - September 14th, 2022 [September 14th, 2022]
- Beyond Bulletproof: Why Billionaires Are Chasing Everlasting Health - Newsweek - September 14th, 2022 [September 14th, 2022]
- Did California Truly Extend the Life of Diablo Canyon? Only Time Will Tell. - JD Supra - September 14th, 2022 [September 14th, 2022]
- Youth Mental Health First Aid Trainings Offered This Fall - Iowa State University - September 14th, 2022 [September 14th, 2022]
- Finland to Extend Validity of Residence Permits for Ukrainian Refugees Under Temporary Protection - SchengenVisaInfo.com - SchengenVisaInfo.com - September 14th, 2022 [September 14th, 2022]
- Wildfire Smoke's Affect on Potato Crops Being Studied - University of Idaho - September 14th, 2022 [September 14th, 2022]
- National Weather Service Northern Indiana radar will be down beginning Monday for upgrades - WANE - September 7th, 2022 [September 7th, 2022]
- Renault Trucks Will Give New Life to Old Parts - Ward's Auto - September 7th, 2022 [September 7th, 2022]
- Stop the stigma and step in - Farm Progress - September 7th, 2022 [September 7th, 2022]
- Empire Wind and WCS Announce Extension of Historic Near Real-Time Acoustic Marine Monitoring Project In New York Bight - Business Wire - September 7th, 2022 [September 7th, 2022]
- Media Advisory: Chalk River Laboratories Officially Breaks Ground on One of the Largest Nuclear Research Facilities Ever Constructed in Canada -... - September 7th, 2022 [September 7th, 2022]
- PFAS pilot study gets yet another extension, scope and cost of another project reduced - wausaupilotandreview.com - September 7th, 2022 [September 7th, 2022]
- Predators extend deal with Bally Sports South - Awful Announcing - September 7th, 2022 [September 7th, 2022]
- WWYDW: Reactions to the Canucks' J.T. Miller extension - Canucks Army - September 7th, 2022 [September 7th, 2022]
- NASA's Artemis rocket makers explain that it's a marathon and a sprint - The Register - September 7th, 2022 [September 7th, 2022]
- Food supply chains are susceptible to fraud and adulteration more than ever, warns Kerry - Food Ingredients First - September 7th, 2022 [September 7th, 2022]
- Reprieve for The White Lady as iconic food truck gets 12-month licence extension - Stuff - September 7th, 2022 [September 7th, 2022]
- Gypsy Moth Biology & Life Cycle - University of Illinois Extension - August 30th, 2022 [August 30th, 2022]
- AgriLife's Johanna Hicks and Team Honored at 2022 National Health Outreach Conference - frontporchnewstexas.com - August 30th, 2022 [August 30th, 2022]
- Harmony Gold to maintain dividends despite facing two years of heavy capital bills - Miningmx - August 30th, 2022 [August 30th, 2022]
- Malaysian, Thai companies ink MOU to explore cooperation in Mechanised Infantry Fighting Vehicle life extension programme - The Edge Markets MY - August 30th, 2022 [August 30th, 2022]
- Coveris previews new packaging solutions targeting enhanced performance and recyclability - Packaging Europe - August 30th, 2022 [August 30th, 2022]
- KPF and heatherwick studio to extend singapore airport as cluster of lush 'neighborhoods' - Designboom - August 30th, 2022 [August 30th, 2022]
- Understanding Tax Liens. Could the IRS seize your car? - finehomesandliving.com - August 30th, 2022 [August 30th, 2022]
- Extension of Legacy Trail in Tyler to continue - Tyler Morning Telegraph - August 29th, 2022 [August 29th, 2022]
- KRUG: Extension learning opportunities around the corner - Hays Post - August 29th, 2022 [August 29th, 2022]
- Half-Life 2 VR is coming, here's how you can get it - Win.gg - August 29th, 2022 [August 29th, 2022]
- Transplant technology: United Therapeutics 3D-printing of human organs focused on every breath you take - Manchester Ink Link - August 29th, 2022 [August 29th, 2022]
- Serena Williams Interview on Leaving Tennis and Her Legacy - TIME - August 29th, 2022 [August 29th, 2022]
- Thousands of photos captured by everyday Australians reveal the secrets of our marine life as oceans warm - The Conversation - August 29th, 2022 [August 29th, 2022]
- Empathy and Solidarity: On Alejandro Varela's The Town of Babylon - lareviewofbooks - August 29th, 2022 [August 29th, 2022]
- How many people continue their stay in the UK or apply to stay permanently? - GOV.UK - August 29th, 2022 [August 29th, 2022]
- Anti-Aging Conference and Olympia Weekend Set for Back-to-Back Weekends in Vegas - Muscle & Fitness - August 15th, 2022 [August 15th, 2022]
- A son steps aboard the Eagle and into his father's world - Journal Inquirer - August 15th, 2022 [August 15th, 2022]
- Class to teach healthy living for those with chronic conditions - The Maryville Forum - August 15th, 2022 [August 15th, 2022]
- New application for disinfection of fresh-cut fruits by means ozone in the packaging - hortidaily.com - August 15th, 2022 [August 15th, 2022]
- Meatless Meats and Smokeless Smokes - Equities News - August 15th, 2022 [August 15th, 2022]
- Command & Control Success: Fireground Commander: Understanding the Impact - Firehouse - August 15th, 2022 [August 15th, 2022]
- Five Ways This Survey About Maine's Wellness is Absolutely Bogus - WJBQ - July 25th, 2022 [July 25th, 2022]
- Center for Advanced Innovation in Agriculture, Virginia Cooperative Extension help Virginia Tech showcase its land-grant mission at 2022 Virginia Ag... - July 25th, 2022 [July 25th, 2022]
- Anti-ageing tips: Here's how to rewind your biological clock - Hindustan Times - July 25th, 2022 [July 25th, 2022]